A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor
to limit the dosage and the continuation of chemotherapy. A newly pegylated rhG-CSF was
independently developed by JIANGSU HENGRUI Medicine Co., Ltd, China. Phase 1a, 1b trials have
shown that pegylated rhG-CSF has decreased renal clearance, increased plasma half-life, and
prolonged efficacy in compare with rhG-CSF. The purpose of this study is to determine the
safety and effectiveness of pegylated rhG-CSF in preventing neutropenia following
chemotherapy in patients with breast cancer.